Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Xanomeline,Trospium
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Schizophrenia Space Anticipates First-in-Class FDA Approval for BMS’ KarXT
Details : Cobenfy (xanomeline-trospium) is an oral, investigational M1/M4 agonist indcated for psychiatric and neurological conditions, including schizophrenia.
Brand Name : Cobenfy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 26, 2024
Lead Product(s) : Xanomeline,Trospium
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?